Get to know our clinical trials
Randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate the efficacy and safety of barzolvolimab in patients with chronic spontaneous urticaria who continue to experience symptoms despite treatment with antihistamines.
THE PURPOSE OF THIS RESEARCH STUDY IS TO TEST THE ACTUAL EFFICACY OF BARZOLVOLIMAB AT 2 DIFFERENT DOSE LEVELS AND TO DETERMINE IF IT HELPS PEOPLE WITH CSU. BARZOLVOLIMAB HAS BEEN TESTED IN 2 STUDIES OF HEALTHY VOLUNTEERS AND 2 STUDIES OF PATIENTS WITH CSU.
Status
In recruitment
headquarters
Pamplona/Madrid
Technical Summary
- PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARZOLVOLIMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA WHO CONTINUE TO EXPERIENCE SYMPTOMS DESPITE TREATMENT WITH H1 ANTIHISTAMINES (EMBARQ - CSU2)
- Code EudraCT: 2024-513210-36-00
- Protocol number: CDX0159-13
- Promoter: Celldex Therapeutics
- Molecule/Drug: Barzolvolimab
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.